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Background: The presence of a patent foramen ovale (PFO) has been associated with an
increase incidence of cryptogenic stroke. Patients who have a PFO and an associated
thrombophilia may have an increased risk of cerebral ischemic events. Percutaneous PFO
closure could be a safe and effective alternative therapeutic approach for these patients.
Methods: Consecutive patients who underwent PFO closure at a large academic centre
were evaluated. All patients underwent hypercoagulation testing with functional assays
for homocysteine; proteins C and S; antithrombin III; factor II mutation; factor V-Leiden
mutation; lipoprotein (a); elevated levels of antiphospholipids; including lupus anticoag-
ulant (LAC), anticardiolipin (aCL). We compared the safety and efficacy of percutaneous
PFO closure in this group of patients versus the group of patients without a hypercoag-
ulable state.
Results: Of 728 consecutive patients with PFO undergoing percutaneous PFO closure, a
hypercoagulable state was found in 234 patients (32.1%). There were no significant
differences on baseline demographics or echocardiographic characteristics. There were no
differences on success rate and complication rate between both groups. Follow up was
available in 708 patients (97.3%). Median follow-up was 17 month. During follow-up
there were no differences in TIA/stroke incidence (0.4% in the group with coagulation
disorder and 0.6% in the non-hypercoagulable group, log rank test p 0.997).
Conclusions: Percutaneous PFO closure is safe and effective therapeutic approach for
patients with criptogenic stroke and an underlying hypercoagulable state.
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Background: Many patients with atrial fibrillation (AF) at high risk for thromboembolic
events are not candidates for long-term oral anticoagulation (OAC). The left atrial
appendage (LAA) is the major site of thrombus formation in non-valvular AF. We report
procedural results with 6 month follow-up for LAA occlusion with the AMPLATZER™
Cardiac Plug (ACP) (St. Jude Medical, Plymouth, MN).
Methods: A total of 197 patients underwent ACP implantation at one of 15 investigative
centers in Europe in 2009-2011. 183 patients have completed their 6 month follow up
visit. Study follow up requirements included echocardiographic assessment at baseline,
pre-discharge 1 and 6 months post implant as well as rigorous neurological exam after a
suspected stroke, TIA or systemic embolism.
Results: The majority of patients (57.9%) had a history of permanent AF, mean age was
74.20 9.0, mean CHADS2 score 2.6 1.3. Prior stroke or TIA was reported by 39.2%
of patients. Patients were indicated for ACP therapy due to bleeding risk on oral
anticoagulation (OAC) (79.8%), prior hemorrhage (8.9%) or prior stroke on Warfarin
(11.3%). Only 3.9% of patients were on active OAC prior to implant. The ACP device
was successfully implanted in 96.6% of patients with a closure rate of 99.5% at implant
and 98.9% at six months. Device/procedure related safety events included: 0 (0.0%)
periprocedural strokes, 3 (1.5%) serious pericardial effusions, 5 (2.4%) device related
thrombus, and 3 (1.5%) device embolizations. The stroke rate was 1.98% at 101 patient
years compared with a CHADS2 prediction of 5.6%.
Conclusions: Although warfarin has been shown to be effective for AF, many patients
with AF are contraindicated for it. The ACP device is a good alternative for these patients
based on the reported excellent implant success, LAA closure, and yields an acceptable
safety profile. The rate of adverse events compares favorably with other LAA closure
devices despite the high risk patients enrolled in the Study.
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Background: Surgical treatment of functional mitral regurgitation (FMR) in the setting
of heart failure has adequate short-term results however, late recurrence of mitral
regurgitation is frequent and associated with high mortality. Patients with dilated left
ventricles (LV) at baseline appear to be a higher risk for early mortality (17.9%) and
readmission (Braun et al., 2008). We sought to determine the outcomes of patients with
FMR and dilated ventricles treated with the MitraClip device.
Methods: Prospective data was collected on patients undergoing therapy with the
MitraClip at the Montreal Heart Institute and Cedars Sinai Medical Center. Echo data was
obtained pre- and post-procedure. Severity of MR was assessed echocardiographically in
accordance with ASE Guidelines. Procedural success was defined as residual MR grade
of 2	 or less. Dilated left ventricle was defined as a left ventricular end-diastolic
dimension (LVEDD) 65mm. Mortality and hospital re-admission data was obtained
from chart review and hospital administration databases.
Results: A total of 70 patients underwent transcatheter leaflet repair with the MitraClip
at both centers during the study period. Ten were identified as having a dilated left
ventricle and significant mitral regurgitation. Procedural success in this group of patients
was 80% (n8). In one patient, we were unable to grasp the leaflets and no clip was
deployed, the patient subsequently died 12 days later from progressive renal failure while
a second patient required mitral valve surgery for persistent severe MR. There were no
procedural complications.
Patient Age
LVEDD
(mm) EF (%)
MR pre-
MitraClip
MR post-
MitraClip Clinical Outcome
1 67 74 25 4 1
2 88 68 30 4 1
3 73 68 60 4 4 Unable to place
clip, died 12d
post-procedure
4 77 66 20 3 2
5 79 76 20 4 2
6 73 83 20 3 1
7 70 70 20 3 3 MVR Day #2 post-
procedure
8 64 68 25 3 2
9 82 75 20 3 1 At 6 month mod
MR, NYHA class I
no admission in
hospital
10 56 81 42 4 2 At one and half
years no
admission for
heart failure,
grade 2 MR NYHA
class I
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